Bellerophon Therapeutics appoints Fares to chief medical officer

Bellerophon Therapeutics Inc., a Warren-based biotherapeutics company, announced on Tuesday it has appointed Wassim Fares to chief medical officer.

Bellerophon, which specializes in developing treatments for cardiopulmonary and infectious diseases,  said Fares is a board-certified pulmonologist and intensive care specialist with more than 20 years of experience in the pharmaceutical industry.

“We are thrilled to welcome Wassim, a seasoned industry leader, to Bellerophon to lead our clinical development at such an important time for the company,” Fabian Tenenbaum, CEO of Bellerophon, said. “Wassim’s deep cardiopulmonary disease expertise as a pulmonologist and principal clinical trial investigator will prove critical to Bellerophon as we advance our two late-stage INOpulse programs in Pulmonary Hypertension associated with Pulmonary Fibrosis (PH-PF) and COVID 19 as well as our other clinical-stage programs in sarcoidosis and chronic obstructive pulmonary disease.”

Most recently, Fares served as the senior medical director at Janssen Pharmaceutical Co. Before that, he consulted on clinical trial strategy for Actelion, Bayer, Gilead and United Therapeutics. He also served in roles in increasing responsibility at Yale University.

“I am excited to join the Bellerophon team and lead the clinical development of the Company’s promising INOpulse therapy program,” Fares said. “The compelling positive results from Bellerophon’s Phase 2 PH-PF trial as well as the patient outcomes observed in the company’s completed COVID-19 Expanded Access Program, highlight INOpulse’s potential to improve outcomes for patients suffering from a number of pulmonary conditions. I look forward to supporting the company in further advancing the ongoing COVID-19 COViNOX Phase 3 trial and initiating the Phase 3 REBUILD study in PH-PF.”